CTX213 Trademark
CTX213 is a USPTO trademark filed by CRISPR Therapeutics AG. Status: Pending.
Trademark Facts
| Mark | CTX213 |
|---|---|
| Serial Number | 98955696 |
| Status | Pending |
| Filing Date | 2025-01-13 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals), 042 (Software & IT) |
| Owner | CRISPR Therapeutics AG |
| Attorney of Record | Tiffany D. Gehrke |
| Prosecution Events | 14 |
| Latest Event | EXRA on 2026-03-13 |
Goods & Services
Cells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes; pharmaceutical and biopharmaceutical agents for the treatment of diabetes; gene editing, namely, pharmaceutical research and development in the field of stem cell therapy for the treatment of diabetes; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of stem cell therapy for the treatment of diabetes